
## Paul D Bieniasz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3529523/publications.pdf Version: 2024-02-01



DALLE D RIENLASZ

#	Article	IF	CITATIONS
1	A diverse range of gene products are effectors of the type I interferon antiviral response. Nature, 2011, 472, 481-485.	13.7	2,054
2	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
3	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008, 451, 425-430.	13.7	1,618
4	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	13.7	1,355
5	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 2020, 9, .	2.8	1,239
6	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
7	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007, 446, 801-805.	13.7	1,082
8	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	13.5	724
9	HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nature Medicine, 2001, 7, 1313-1319.	15.2	676
10	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 384, 2212-2218.	13.9	647
11	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	13.7	610
12	Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell, 2009, 139, 499-511.	13.5	517
13	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	4.2	503
14	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	13.7	463
15	MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature, 2013, 502, 563-566.	13.7	445
16	HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006940-a006940.	2.9	421
17	Intrinsic immunity: a front-line defense against viral attack. Nature Immunology, 2004, 5, 1109-1115.	7.0	396
18	Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. Cell Host and Microbe, 2009, 6, 409-421.	5.1	391

#	Article	IF	CITATIONS
19	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	5.8	379
20	Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12414-12419.	3.3	375
21	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. New England Journal of Medicine, 2022, 386, 599-601.	13.9	371
22	Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Medicine, 2003, 9, 1138-1143.	15.2	362
23	Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. Journal of Virology, 2009, 83, 1837-1844.	1.5	347
24	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5Â. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10774-10779.	3.3	345
25	CG dinucleotide suppression enables antiviral defence targeting non-self RNA. Nature, 2017, 550, 124-127.	13.7	336
26	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	5.8	332
27	Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. Cell Host and Microbe, 2009, 6, 54-67.	5.1	324
28	Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly. PLoS Biology, 2006, 4, e435.	2.6	299
29	Imaging the biogenesis of individual HIV-1 virions in live cells. Nature, 2008, 454, 236-240.	13.7	290
30	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	4.2	283
31	Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants. PLoS Pathogens, 2009, 5, e1000300.	2.1	273
32	APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles. Journal of Virology, 2004, 78, 12058-12061.	1.5	264
33	Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11914-11919.	3.3	261
34	Reconstitution of an Infectious Human Endogenous Retrovirus. PLoS Pathogens, 2007, 3, e10.	2.1	249
35	Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO Journal, 1998, 17, 7056-7065.	3.5	245
36	An Interferon-α-Induced Tethering Mechanism Inhibits HIV-1 and Ebola Virus Particle Release but Is Counteracted by the HIV-1 Vpu Protein. Cell Host and Microbe, 2007, 2, 193-203.	5.1	241

#	Article	IF	CITATIONS
37	HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane. PLoS Pathogens, 2006, 2, e39.	2.1	239
38	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
39	Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19114-19119.	3.3	233
40	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. Journal of Infectious Diseases, 2021, 223, 389-398.	1.9	233
41	Role of ESCRT-I in Retroviral Budding. Journal of Virology, 2003, 77, 4794-4804.	1.5	231
42	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
43	Natural Variation in Vif: Differential Impact on APOBEC3C/3F and a Potential Role in HIV-1 Diversification. PLoS Pathogens, 2005, 1, e6.	2.1	226
44	Human Tripartite Motif 5α Domains Responsible for Retrovirus Restriction Activity and Specificity. Journal of Virology, 2005, 79, 8969-8978.	1.5	223
45	Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO Journal, 2003, 22, 385-394.	3.5	216
46	Global Changes in the RNA Binding Specificity of HIV-1 Gag Regulate Virion Genesis. Cell, 2014, 159, 1096-1109.	13.5	216
47	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. Cell Host and Microbe, 2016, 20, 392-405.	5.1	215
48	Dynamics of ESCRT protein recruitment during retroviral assembly. Nature Cell Biology, 2011, 13, 394-401.	4.6	198
49	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	13.7	197
50	HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. Journal of Cell Biology, 2005, 168, 89-101.	2.3	184
51	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3563-3568.	3.3	183
52	Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells. Journal of Virology, 2005, 79, 176-183.	1.5	180
53	Extreme Genetic Fragility of the HIV-1 Capsid. PLoS Pathogens, 2013, 9, e1003461.	2.1	178
54	Multiple Blocks to Human Immunodeficiency Virus Type 1 Replication in Rodent Cells. Journal of Virology, 2000, 74, 9868-9877.	1.5	176

#	Article	IF	CITATIONS
55	The Cell Biology of HIV-1 Virion Genesis. Cell Host and Microbe, 2009, 5, 550-558.	5.1	175
56	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	13.7	174
57	Analysis of the Initiating Events in HIV-1 Particle Assembly and Genome Packaging. PLoS Pathogens, 2010, 6, e1001200.	2.1	162
58	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. Journal of Clinical Microbiology, 2020, 58, .	1.8	154
59	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	13.7	154
60	A macaque model of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4425-4429.	3.3	150
61	Host and Viral Determinants of Mx2 Antiretroviral Activity. Journal of Virology, 2014, 88, 7738-7752.	1.5	144
62	SAMHD1-dependent retroviral control and escape in mice. EMBO Journal, 2013, 32, 2454-2462.	3.5	141
63	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. Science, 2006, 314, 95-95.	6.0	140
64	A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation. Cell, 2015, 160, 631-643.	13.5	137
65	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature, 2020, 582, 438-442.	13.7	136
66	Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity. Journal of Virology, 2005, 79, 15567-15572.	1.5	133
67	Context-Dependent Effects of L Domains and Ubiquitination on Viral Budding. Journal of Virology, 2004, 78, 5554-5563.	1.5	129
68	The RING-CH Ligase K5 Antagonizes Restriction of KSHV and HIV-1 Particle Release by Mediating Ubiquitin-Dependent Endosomal Degradation of Tetherin. PLoS Pathogens, 2010, 6, e1000843.	2.1	129
69	A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. Journal of Cell Biology, 2009, 184, 881-894.	2.3	120
70	Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid. Journal of Virology, 2004, 78, 6005-6012.	1.5	119
71	Human Immunodeficiency Virus, Restriction Factors, and Interferon. Journal of Interferon and Cytokine Research, 2009, 29, 569-580.	0.5	116
72	Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18097-18101.	3.3	112

#	Article	IF	CITATIONS
73	Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection. Journal of Virology, 2002, 76, 6332-6343.	1.5	111
74	HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. Cell, 2016, 166, 1257-1268.e12.	13.5	110
75	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	13.7	108
76	Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24303-24309.	3.3	106
77	Vpu Binds Directly to Tetherin and Displaces It from Nascent Virions. PLoS Pathogens, 2013, 9, e1003299.	2.1	102
78	Restriction factors: a defense against retroviral infection. Trends in Microbiology, 2003, 11, 286-291.	3.5	100
79	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. ELife, 2018, 7, .	2.8	100
80	Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18428-18432.	3.3	97
81	Mechanism of HIV-1 Virion Entrapment by Tetherin. PLoS Pathogens, 2013, 9, e1003483.	2.1	97
82	Intrinsic Cellular Defenses against Human Immunodeficiency Viruses. Immunity, 2012, 37, 399-411.	6.6	96
83	Integration target site selection by a resurrected human endogenous retrovirus. Genes and Development, 2009, 23, 633-642.	2.7	95
84	Temporal and spatial organization of ESCRT protein recruitment during HIV-1 budding. Proceedings of the United States of America, 2014, 111, 12211-12216.	3.3	93
85	A Comparative Study of Higher Primate Foamy Viruses, Including a New Virus from a Gorilla. Virology, 1995, 207, 217-228.	1.1	88
86	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology, 2006, 349, 31-40.	1.1	88
87	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	6.6	86
88	Hypermutation of an Ancient Human Retrovirus by APOBEC3G. Journal of Virology, 2008, 82, 8762-8770.	1.5	84
89	Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection. PLoS Pathogens, 2013, 9, e1003214.	2.1	82
90	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	2.9	80

#	Article	IF	CITATIONS
91	Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions. Journal of Virology, 2004, 78, 9560-9563.	1.5	79
92	Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20031-20036.	3.3	77
93	HIV-1–induced AIDS in monkeys. Science, 2014, 344, 1401-1405.	6.0	76
94	Co-option of an endogenous retrovirus envelope for host defense in hominid ancestors. ELife, 2017, 6,	2.8	75
95	Visualizing HIV-1 Assembly. Journal of Molecular Biology, 2011, 410, 501-511.	2.0	73
96	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	13.5	73
97	HIV/AIDS: in search of an animal model. Trends in Biotechnology, 2007, 25, 333-337.	4.9	72
98	Identification of Human VPS37C, a Component of Endosomal Sorting Complex Required for Transport-I Important for Viral Budding. Journal of Biological Chemistry, 2005, 280, 628-636.	1.6	71
99	Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates. Journal of Virology, 1998, 72, 1918-1924.	1.5	71
100	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clinical Infectious Diseases, 2021, 73, e1208-e1211.	2.9	65
101	No Evidence of Antibody to Human Foamy Virus in Widespread Human Populations. AIDS Research and Human Retroviruses, 1996, 12, 1473-1483.	0.5	61
102	SIV Nef Proteins Recruit the AP-2 Complex to Antagonize Tetherin and Facilitate Virion Release. PLoS Pathogens, 2011, 7, e1002039.	2.1	59
103	Single-Cell and Single-Cycle Analysis of HIV-1 Replication. PLoS Pathogens, 2015, 11, e1004961.	2.1	58
104	Functional Interchangeability of Late Domains, Late Domain Cofactors and Ubiquitin in Viral Budding. PLoS Pathogens, 2010, 6, e1001153.	2.1	57
105	A Bipartite Late-Budding Domain in Human Immunodeficiency Virus Type 1. Journal of Virology, 2003, 77, 12373-12377.	1.5	55
106	Inhibition of HIV-1 Particle Assembly by 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase. Cell Host and Microbe, 2012, 12, 585-597.	5.1	54
107	The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. PLoS Pathogens, 2016, 12, e1005833.	2.1	54
108	Primate Lentivirus Capsid Sensitivity to TRIM5 Proteins. Journal of Virology, 2008, 82, 6772-6777.	1.5	51

#	Article	IF	CITATIONS
109	Sequences in <i>pol</i> Are Required for Transfer of Human Foamy Virus-Based Vectors. Journal of Virology, 1998, 72, 5510-5516.	1.5	51
110	Multiple, Switchable Protein:RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. Annual Review of Virology, 2018, 5, 165-183.	3.0	50
111	Replication and single-cycle delivery of SARS-CoV-2 replicons. Science, 2021, 374, 1099-1106.	6.0	49
112	Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases, 2021, 27, 2454-2458.	2.0	48
113	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. Cell Host and Microbe, 2014, 16, 412-418.	5.1	47
114	Analysis of the human immunodeficiency virus-1 RNA packageome. Rna, 2016, 22, 1228-1238.	1.6	46
115	Clathrin Facilitates the Morphogenesis of Retrovirus Particles. PLoS Pathogens, 2011, 7, e1002119.	2.1	45
116	Tetherin Promotes the Innate and Adaptive Cell–Mediated Immune Response against Retrovirus Infection In Vivo. Journal of Immunology, 2014, 193, 306-316.	0.4	45
117	Capsid-Dependent and -Independent Postentry Restriction of Primate Lentivirus Tropism in Rodent Cells. Journal of Virology, 2004, 78, 1006-1011.	1.5	43
118	HIV-1 at 25. Cell, 2008, 133, 561-565.	13.5	43
119	Identification of Domains in Gag Important for Prototypic Foamy Virus Egress. Journal of Virology, 2005, 79, 6392-6399.	1.5	41
120	Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism. Molecular and Cellular Biology, 1999, 19, 4592-4599.	1.1	40
121	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	7.0	40
122	Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication. PLoS Pathogens, 2018, 14, e1006824.	2.1	37
123	HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. ELife, 2020, 9, .	2.8	37
124	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. ELife, 2021, 10, .	2.8	36
125	No effect of endogenous TRIM5α on HIV-1 production. Nature Medicine, 2008, 14, 235-236.	15.2	35
126	Origins and Evolution of tetherin , an Orphan Antiviral Gene. Cell Host and Microbe, 2016, 20, 189-201.	5.1	35

#	Article	IF	CITATIONS
127	Analysis of the Effect of Natural Sequence Variation in Tat and in Cyclin T on the Formation and RNA Binding Properties of Tat-Cyclin T Complexes. Journal of Virology, 1999, 73, 5777-5786.	1.5	35
128	Evidence for Restriction of Ancient Primate Gammaretroviruses by APOBEC3 but Not TRIM5α Proteins. PLoS Pathogens, 2008, 4, e1000181.	2.1	33
129	Origin and evolution of the zinc finger antiviral protein. PLoS Pathogens, 2021, 17, e1009545.	2.1	33
130	Effect of DNA Repair Protein Rad18 on Viral Infection. PLoS Pathogens, 2006, 2, e40.	2.1	32
131	Antiretroviral restriction factors. Current Opinion in Virology, 2011, 1, 526-532.	2.6	32
132	Assisted Evolution Enables HIV-1 to Overcome a High TRIM5α-Imposed Genetic Barrier to Rhesus Macaque Tropism. PLoS Pathogens, 2013, 9, e1003667.	2.1	32
133	The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles. Journal of Virology, 2006, 80, 12102-12108.	1.5	30
134	Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses. Journal of Virology, 2013, 87, 3549-3560.	1.5	28
135	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	2.1	28
136	Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State. Journal of Virology, 2019, 93, .	1.5	28
137	Role Of Chemokine Receptors In Hiv-1 Infection And Pathogenesis. Advances in Virus Research, 1999, 52, 233-267.	0.9	27
138	Identification of a receptor for an extinct virus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19496-19501.	3.3	27
139	The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. ELife, 2018, 7, .	2.8	27
140	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Reports Medicine, 2021, 2, 100164.	3.3	26
141	Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells. Journal of Virology, 2005, 79, 15586-15589.	1.5	25
142	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	5.1	23
143	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. Cell Host and Microbe, 2021, 29, 1421-1436.e7.	5.1	22
144	The Case Against Delaying Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine Boosting Doses. Clinical Infectious Diseases, 2021, 73, 1321-1323.	2.9	22

#	Article	IF	CITATIONS
145	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. Lancet Microbe, The, 2022, 3, e493-e502.	3.4	22
146	Uneven Genetic Robustness of HIV-1 Integrase. Journal of Virology, 2015, 89, 552-567.	1.5	20
147	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
148	Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing. Journal of Virology, 2019, 93, .	1.5	19
149	Poly(ADP-ribose) potentiates ZAP antiviral activity. PLoS Pathogens, 2022, 18, e1009202.	2.1	19
150	An overview of intracellular interactions between immunodeficiency viruses and their hosts. Aids, 2012, 26, 1243-1254.	1.0	18
151	Cyclin T1 Expression Is Mediated by a Complex and Constitutively Active Promoter and Does Not Limit Human Immunodeficiency Virus Type 1 Tat Function in Unstimulated Primary Lymphocytes. Journal of Virology, 2002, 76, 208-219.	1.5	16
152	Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis. Journal of Virology, 2017, 91, .	1.5	16
153	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathogens, 2021, 17, e1009688.	2.1	16
154	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10504-10509.	3.3	14
155	CLIP-related methodologies and their application to retrovirology. Retrovirology, 2018, 15, 35.	0.9	12
156	Mechanisms of Attenuation by Genetic Recoding of Viruses. MBio, 2021, 12, .	1.8	12
157	Reconstruction of a replication-competent ancestral murine endogenous retrovirus-L. Retrovirology, 2018, 15, 34.	0.9	11
158	Inhibition of spumavirus gene expression by PHF11. PLoS Pathogens, 2020, 16, e1008644.	2.1	11
159	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	4.2	10
160	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. MBio, 2022, 13, .	1.8	9
161	An intrinsic host defense against HIV-1 integration?. Journal of Clinical Investigation, 2007, 117, 302-304.	3.9	8
162	Derivation and characterization of an HIV-1 mutant that rescues IP6 binding deficiency. Retrovirology, 2021, 18, 25.	0.9	7

#	Article	IF	CITATIONS
163	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. ELife, 2019, 8, .	2.8	6
164	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLoS ONE, 2022, 17, e0266086.	1.1	6
165	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	4.2	6
166	VPS29 Exerts Opposing Effects on Endocytic Viral Entry. MBio, 2022, 13, e0300221.	1.8	5
167	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
168	Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). Journal of Medical Virology, 1994, 43, 28-32.	2.5	4
169	Repurposing a Bacterial Immune System to Discover Antiviral Targets. New England Journal of Medicine, 2017, 376, 1290-1291.	13.9	3
170	A multimodal antiretroviral protein. Nature Microbiology, 2018, 3, 122-123.	5.9	3
171	Functional Differences between Human and Bovine Immunodeficiency Virus Tat Transcription Factors. Journal of Virology, 2000, 74, 4666-4671.	1.5	3
172	Sensing Retroviruses. Immunity, 2011, 35, 8-10.	6.6	2
173	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. Journal of Clinical Virology Plus, 2021, 1, 100028.	0.4	2
174	Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. AIDS Research and Human Retroviruses, 2019, 35, 473-476.	0.5	0